Mode
Text Size
Log in / Sign up

Low antimicrobial resistance in Lawsonella clevelandensis infections suggests susceptibility to penicillins, carbapenems, clindamycin, and metronidazoleDoctors find specific bacteria cause deep abscesses in fat tissue

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that L. clevelandensis shows low minimum inhibitory concentrations for several common antibiotics in deep-seated abscesses.

This narrative review synthesizes data from 27 publications, including 18 clinical cases, concerning Lawsonella clevelandensis infections in deep-seated abscesses. The authors identify a predilection for fat-rich tissues such as the breast and abdomen, with potential associations between infection and host factors like diabetes, immunosuppression, and prior surgical procedures.

Genomic analysis via whole-genome sequencing revealed no acquired resistance genes. Furthermore, single strain testing showed uniformly low minimum inhibitory concentrations for penicillins, carbapenems, clindamycin, and metronidazole. These findings suggest that the organism remains susceptible to these primary antibiotic classes despite its presence in complex clinical scenarios.

Significant limitations include a limited number of tested isolates and a lack of established clinical breakpoints, which preclude definitive conclusions regarding universal susceptibility. Clinicians are advised to maintain a high index of suspicion for L. clevelandensis in culture-negative deep abscesses, particularly those characterized by acid-fast rods. Practice relevance is tempered by the need for further isolate testing to establish broader clinical guidelines.

How this fits prior evidence

This narrative review addresses a gap in the management of specific infections caused by Lawsonella clevelandensis. While prior coverage has addressed antibiotic resistance mutations in H. pylori and high rates of penicillin resistance in K. pneumoniae, this evidence suggests that L. clevelandensis currently shows uniformly low minimum inhibitory concentrations for penicillins, carbapenems, clindamycin, and metronidazole without identified acquired resistance genes.

When a patient develops a deep-seated abscess that does not respond well to standard treatment, doctors may be facing a tricky culprit. A review of cases involving Lawsonella clevelandensis shows this bacterium has a strong preference for fat-rich tissues, such as those found in the breast and abdomen.

Researchers looked at 27 publications, including 18 clinical cases, to understand how this germ behaves. They found that while it is often hard to detect, it shows low resistance to common antibiotics like penicillins, carbapenems, clindamycin, and metronidazole. Interestingly, genetic testing showed no signs of acquired resistance genes, meaning the bacteria are naturally susceptible to these drugs.

Because this infection can appear in culture-negative cases, doctors are urged to stay alert. It is especially important to look for it when patients have risk factors like diabetes, a weakened immune system, or a history of surgery. Because there are so few tested samples available, experts still need more data to set firm rules for treatment.

What this means for you:
Lawsonella clevelandensis often causes deep abscesses in fat-rich tissues and is generally susceptible to common antibiotics.

Common questions

What types of tissue is this bacteria most likely to affect?

This bacterium has a known preference for fat-rich tissues. Specifically, it is often found in infections involving the breast and abdomen. Because it likes these areas, doctors should keep a high level of suspicion when treating deep abscesses in these locations.

Is this infection resistant to common antibiotics?

The study found that the bacteria showed low minimum inhibitory concentrations for several common drugs, including penicillins, carbapenems, clindamycin, and metronidazole. Genomic analysis also showed no acquired resistance genes were present in the samples tested.

Who is at higher risk for this specific infection?

While not a certainty, there are potential links between this infection and certain health factors. These include having diabetes, being immunocompromised, or having undergone prior surgical procedures. You should talk to your doctor about these risks if you have a deep infection.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedAug 2026
View Original Abstract ↓
Since its formal description in 2016, Lawsonella clevelandensis—a strictly anaerobic, partially acid-fast bacterium—has been increasingly recognized as a cause of deep-seated abscesses, yet its fastidious nature and absence from routine diagnostic databases contribute to significant underdiagnosis. This narrative review synthesizes current knowledge on its microbiology, expanding clinical spectrum, diagnostic strategies, and treatment, based on a literature search of PubMed and Web of Science up to April 2026. Analysis of 27 documented publications, comprising 18 clinical cases, reveals a potential association with host risk factors including diabetes, immunosuppression, and prior surgical procedures, alongside a notable predilection for fat-rich tissues such as the breast and abdomen. While metagenomic next-generation sequencing and 16S rRNA gene amplification have become indispensable for definitive identification, antimicrobial susceptibility data—derived primarily from a single strain—demonstrate uniformly low minimum inhibitory concentrations for penicillins, carbapenems, clindamycin, and metronidazole, with no acquired resistance genes identified by whole-genome sequencing. However, the absence of established clinical breakpoints and limited tested isolates precludes definitive conclusions about universal susceptibility. Clinicians should maintain a high index of suspicion for L. clevelandensis in culture-negative deep abscesses, particularly those with acid-fast rods, as prompt diagnosis and empirical therapy with β-lactam/β-lactamase inhibitors or carbapenems appear reasonable based on current in vitro and clinical evidence, though further susceptibility surveillance is essential.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.